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1. Introduction
Zinc (Zn) is an essential trace element for most organisms. It plays important roles in vari‐
ous physiological functions such as the mitotic cell division, the immune system, the synthe‐
sis of proteins and DNA as a co-factor of more than 300 enzymes or metalloproteins [1].
Recent studies revealed that Zn signaling plays crucial roles in various biological systems of
humans [2]. Zn deficiency in human childhood is known to cause the dwarfism, the retarda‐
tion of mental and physical development, the immune dysfunction, and the learning disabil‐
ities [3]. In adults, Zn deficiency causes the taste and odor disorders.
The human body contains approximately 2 g of Zn, mostly in the testes, muscle, liver, and
brain tissues. In the brain, Zn is found at the highest concentrations in the hippocampus,
amygdala, cerebral cortex, thalamus, and olfactory cortex [4]. The total Zn content of the
hippocampus is estimated to be 70–90 ppm (dry weight). Although some Zn in the brain
binds firmly to metalloproteins or enzymes, a substantial fraction (approximately 10% or
more) either forms free Zn ions (Zn2+) or is loosely bound, and is histochemically detectable
by staining using chelating reagents. This chelatable Zn is stored in presynaptic vesicles of
specific excitatory glutamatergic neurons and is secreted from these vesicles into synaptic
clefts along with glutamate during neuronal excitation. Recent studies have suggested that
this secreted Zn2+ plays crucial roles in information processing, synaptic plasticity, learning,
and memory (Fig. 1A). Indeed, Zn2+ in the hippocampus is essential for the induction of
long-term potentiation (LTP), a form of synaptic information storage that has become a well-
known paradigm for the mechanisms underlying memory formation [5].
However, despite its importance, excess Zn is neurotoxic and implicated in neurodegenera‐
tive diseases. In this chapter, we review the current understanding about the link between
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the disruption of Zn homeostasis and the pathogenesis of various neurodegenerative diseas‐
es including senile dementia.
2. Zinc and vascular type of dementia
2.1. Zn-induced neurodegeneration after ischemia
Senile dementia is a serious problem in a rapidly aging world. Its prevalence increases with
age. Approximately 25% of elderly individuals are affected by the diseases. In Japan, 3 mil‐
lion people have been estimated to be affected by senile dementia by 2025, and the number
continues to grow annually. Senile dementia is mainly divided to Alzheimer’s disease (AD)
and vascular-type dementia (VD). VD is a degenerative cerebrovascular disease, and its risk
factors include aging, sex difference (male), diabetes, and high blood pressure. The most
common type of VD is caused by a series of small strokes or ischemia [6]. Following transi‐
ent global ischemia or stroke, the interruption of blood flow and the resulting oxygen-glu‐
cose deprivation induce long-lasting membrane depolarization and cause an excessive
release of glutamate into synaptic clefts. Thereafter, the excess glutamate causes over-stimu‐
lation of its receptors, namely, N-methyl-D-aspartate (NMDA)-type receptors, amino-3-hy‐
droxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type receptors, and kainite-type
receptors. Finally, Ca2+ dyshomeostasis, i.e., the entry of large quantities of Ca2+ occurring in
glutamate-responsive neurons, triggers the delayed death of vulnerable populations of neu‐
rons such as pyramidal neurons in the hippocampus —an area associated with learning and
memory. Thereafter, the development of an infarct and the subsequent cognitive dysfunc‐
tion mark the pathogenesis of VD in elderly people. Approximately 30% of stroke patients
show symptoms of dementia within 3 months of the initial stroke [7].
Increasing evidence suggests that Zn is central to ischemia-induced neuronal death and fi‐
nally the pathogenesis of VD [8]. In ischemic conditions, a considerable amount of Zn (up to
300µM) is co-released with glutamate into synaptic clefts by membrane depolarization. Zn
caused the apoptotic death of primary cultured cortical neurons. Furthermore, the chelata‐
ble Zn reportedly moved from presynaptic terminals into postsynaptic neuronal cell bodies.
The increase in intracellular Zn2+ levels ([Zn2+]i), namely, “Zn translocation,” occurs in vul‐
nerable neurons in the CA1 or CA3 regions of the hippocampus prior to the onset of the de‐
layed neuronal death after transient global ischemia [9]. This Zn translocation is reported to
enhance the appearance of the infarct. Administration of calcium EDTA (Ca EDTA), a mem‐
brane-impermeable chelator that chelates cations except for calcium, blocked the transloca‐
tion of Zn, protected the hippocampal neurons after transient global ischemia, and reduced
the infarct volume [10]. Thus, Zn translocation is recognized to be the primary event in the
pathway of Zn-induced neuronal death. Sensi et al. observed a temporal change of [Zn2+]i in
cultured cortical neurons using a zinc-sensitive fluorescent dye; those results revealed that
at least three major routes of Zn2+ entry have been identified; voltage-gated Ca2+ channels
(VGLC), NMDA-type glutamate receptors (NMDA-R), and AMPA/kainite-type glutamate
receptors (A/K-R). Although the NMDA-type glutamate receptors are present in most neu‐
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rons, the permeablity of Zn2+ and Ca2+ through AMPA/kainate channels is greater than
NMDA-receptor channels [11].
In a normal condition, most hippocampal neurons express AMPA receptors with subunit
GluR2,  which are  poorly  permeable  to  divalent  cations  including Ca2+  and Zn2+(A/K-R).
However, after ischemia, the acute reduction in the expression of GluR2 subunit occurs,
and neurons  possess  specific  type  of  AMPA receptors  which  channels  are  directly  Ca2+
permeable  (Ca-AMPA/kainate  channels;  Ca-A/K-R))  [12].  The  appearance  of  Ca-AMPA/
kainate  channels  causes  the  increased  permeability  of  Ca2+  and  enhances  the  toxicity.
Therefore,  the expression of Zn2+-permeable Ca-AMPA/kainite channels and the entry of
Ca2+  and/or Zn2+  through the channels are mediators of the delayed neuronal death after
ischemia.  Considering  that  Ca  EDTA,  a  zinc  chelator,  attenuates  the  ischemia-induced
down-regulation of  GluR2 gene [10],  Zn is  also implicated in the transcriptional  regula‐
tion in Ca-AMPA/kainite channels.
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Figure 1. Zinc in normal or pathological conditions in the brain. Under normal conditions (A), neuronal excitation
causes the release of glutamate and Zn. Zn regulates the postsynaptic excitability by binding to NMDA-type glutamate
receptors (NMDA-R). However, under pathological conditions such as ischemia (B), oxygen-glucose deprivation indu‐
ces the release of excess glutamate as well as Zn into the synaptic clefts. Excess Zn enhances the expression of Ca-
AMPA/kainite channels (Ca-A/K-R), and is translocated through the Ca-A/K-R or through other pathways such as
voltage-gated L-type Ca2+ channels (VGLC) into the target neuron, where Zn acts to inhibit various enzymes, inhibit
mitochondrial respiration, cause energy depletion, and produce reactive reactive oxygen species (ROS). Excess gluta‐
mate induces elevation of intracellular Ca2+ levels in the target neuron. Elevated levels of intracellular Ca2+ then trigger
various apoptotic pathways such as the activation of calpain, caspases or other enzymatic pathways related to apop‐
tosis; ultimately this leads to neuronal death.
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Zn-specific membrane transporter proteins (Zn transporters) also control Zn homeostasis;
they facilitate zinc influx in deficiency and efflux during zinc excess. Recent genetic and
molecular  approaches  revealed  the  implications  of  abnormalities  in  Zn  transporters  in
various  human  diseases  [13].  Zn  transporter  1  (ZnT-1),  a  membrane  protein  with  six
transmembrane  domains,  is  widely  distributed  in  mammalian  cells,  and  is  co-localized
with  chelatable  Zn in  the  brain.  ZnT-1  is  activated by excess  Zn and the  expression of
ZnT-1 is  induced after  transient  global  ischemia.  On the contrary,  dietary Zn deficiency
decreases  expression  of  ZnT-1.  Consequently,  it  is  provable  that  ZnT-1  plays  a  pivotal
role in efflux of Zn and in protection from Zn toxicity. Another important Zn transporter
in  the  brain  is  ZnT-3,  which  localizes  in  the  membranes  of  presynaptic  vesicles,  trans‐
ports Zn into synaptic vesicles, and maintains high Zn concentrations in the vesicles. Al‐
though the physiological  role of ZnT-3 and vesicular zinc remain elusive,  recent studies
have suggested the implication of ZnT-3 or other Zn transporters in the pathogenesis of
AD and other neurodegenerative diseases [14].
2.2. Molecular mechanism of Zn-induced neurotoxicity: GT1-7 cells as an in vitro model
system
Understanding the molecular mechanism of Zn-induced neuronal death is of great impor‐
tance for the treatment of VD. Numerous studies have been undertaken to elucidate the
mechanism of Zn-induced neuronal death. To this end, many researchers have investigated
Zn neurotoxicity in vitro mainly using primary cultured neurons from rat cerebral cortex or
hippocampus [15] or PC-12 cells, a pheochromocytoma cell line [16]. However, the roles of
Zn are highly complex. For example, Zn reportedly inhibits NMDA-type glutamate recep‐
tors and regulates the excitability of glutamatergic neurons, which are toxic to neurons.
Therefore, distinguishing of the effects of Zn and glutamate by using neuronal cells which
possess glutamate receptors has proved difficult.
We found that GT1-7 cells, immortalized hypothalamic neurons, are much more sensitive to
Zn than other neuronal cells are [17,18] (Fig. 2A). Zn caused the apoptotic death of GT1-7
cells in a dose-dependent and time-dependent manner. The degenerated GT1-7 cells were
terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick-end labeling (TU‐
NEL) positive and exhibited the DNA fragmentation.
The  GT1-7  cells  were  originally  developed by  Mellon  et  al.  by  genetically  targeting  tu‐
morigenesis of mouse hypothalamic neurons [19]. The cells possess neuronal characteris‐
tics  such  as  the  extension  of  neurites,  secretion  of  gonadotropin-releasing  hormone
(GnRH),  and expression  of  neuron-specific  proteins  or  receptors  including  microtubule-
associated  protein  2  (MAP2),  tau  protein,  neurofilament,  synaptophysin,  GABAA  recep‐
tors,  dopamine receptors,  and L-type Ca2+  channels.  Additionally,  the  GT1-7  cells  either
lack or possess low levels of ionotropic glutamate receptors and do not exhibit glutamate
toxicity [20]. These properties make the GT1-7 cell line an excellent model system for the
investigation of Zn-induced neurotoxicity.
We investigated the detailed characteristics of Zn-induced death in GT1-7 cells and its mech‐
anisms. First, we tested the effects of various pharmacological agents prior to Zn treatment
Neurodegenerative Diseases522
of GT1-7 cells. Neither antagonists nor agonists of excitatory neurotransmitters (D-APV, glu‐
tamate, and CNQX), or those of inhibitory neurotransmitters (bicuculline, muscimol, baclo‐
fen, and GABA) attenuated the viability of GT1-7 cells after Zn exposure. Our findings in
GT1-7 cells, which lack such glutamate receptors, are inconsistent with previous studies that
agonists of glutamate receptors, such as NMDA or AMPA, enhance Zn-induced neurotoxici‐
ty in cultured cortical neurons [21].
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Figure 2. Apoptotic death of GT1-7 cells after exposure to Zn. A: Viability of various neuronal cells after exposure to
Zn. Cultured neuronal cells (GT1-7 cells, PC-12 cells, B-50 cells (a neuroblastoma cell line), primary cultured neurons of
the rat cerebral cortex, and primary cultured neurons of the rat hippocampus) were administered to 50 µM of Zn. Af‐
ter 24h, cell viability was analyzed by WST-1 method. B: TUNEL staining of Zn intoxicated GT1-7 cells GT1-7 cells were
exposed to 50 µM Zn, and were observed with TUNEL staining after 24h.
To evaluate the involvement of other metal ions in Zn neurotoxicity, we investigated the vi‐
ability of GT1-7 cells with or without various metal ions after exposure to Zn [22]. The equi‐
molar addition of Al3+ and Gd3+ significantly inhibited Zn-induced neurotoxicity. Moreover,
overloading of Ca2+ and Mg2+ inhibited the Zn-induced death of GT1-7 cells; Zn protected
GT1-7 cells from neurotoxicity induced by Ca2+ overload, and vice versa (Fig. 3B). Further‐
more, Kim et al. reported that Zn neurotoxicity in PC-12 cells was attenuated by an L-type
Ca2+ channel blocker, nimodipine, and enhanced by the L-type Ca2+ channel activator, S(-)-
Bay K 8644 [16]. Additionally, Zn neurotoxicity was attenuated by aspirin, which prevents
Zn2+ entry through voltage-gated Ca2+ channels. These pharamacological evidence suggests
that Ca dyshomeostasis is involved in the mechanism of Zn-induced neurotoxicity.
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Figure 3. Effects of various pharmacological substances on Zn-induced death of GT1-7 cells. A: GT1-7 cells were ex‐
posed to 50µM of Zn2+ with agonists or antagonisits of neurotransmitters (D-APV (D-2-amino-5-phosphonovalerate),
glutamate, CNQX (6-cyano-7-nitroquinoxaline-2,3-dione), bicuculline, muscimol, baclofen, GABA (gamma-aminobuty‐
ric acid)), channel blockers (TTX(tetrodotoxin), nimodipine), etc. B: GT1-7 cells were exposed to Zn2+ with or without
Ca2+.
2.3. Implication of Ca dyshomeostasis in Zn-induced neuronal death
To address this issue, we employed a high-resolution multi-site video imaging system with
fura-2 as the cytosolic free calcium reporter fluorescent probe for the observation of tempo‐
ral changes in [Ca2+]i after exposure to Zn (Fig. 4). This multisite fluorometry system enables
the simultaneous long-term observation of temporal changes in [Ca2+]i of more than 50 neu‐
rons. The elevations in [Ca2+]i were observed among GT1-7 cells after 3-30 min of the expo‐
sure to Zn [18]. Detailed analysis of Zn-induced [Ca2+]i revealed that pretreatment of Al3+
significantly blocked the Zn-induced [Ca2+]i elevations. Thus, it is possible that Al3+, a known
blocker of various types of Ca2+ channels, attenuate Zn-induced neurotoxicity by blocking
Zn-induced elevations in [Ca2+]i.
We also showed that the administration of sodium pyruvate, an energy substrate, signifi‐
cantly inhibited the Zn-induced death of GT1-7 cells [17]. The results are consistent with
findings of other studies using primary cultured cortical neurons, oligodendrocyte progeni‐
tor cells, or retinal cells. Furthermore, the administration of pyruvate attenuated the neuro‐
nal death after ischemia in vivo [23]. Shelline and his colleagues reported that Zn exposure
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decreased the levels of NAD+ and ATP in cultured cortical neurons, and that treatment with
pyruvate restored the NAD+ level [24]. An imaging study using a Zn-sensitive fluorescent
dye and a mitochondrial marker revealed that Zn is localized within mitochondria. Zn is re‐
ported to inhibit various mitochondrial enzymes and the intracellular trafficking of mito‐
chondria. It has also been reported that Zn produced ROS and caused oxidative damage
resulting from mitochondrial impairments. Therefore, energy failure and the inhibition of
glycolysis in mitochondria may be involved in Zn neurotoxicity [25].
2.4. Carnosine as an endogenous protective substance against Zn neurotoxicity
Considering the implication of Zn in transient global ischemia, substances that protect
against Zn-induced neuronal death could be potential candidates for the prevention or treat‐
ment of neurodegeneration following ischemia, and ultimately provide a lead to treatments
for VD. With the aim of exploring this idea, we developed a rapid, sensitive, and convenient
assay system for the mass-screening of such substances by using GT1-7 cells. We examined
the potential inhibitory effects of various agricultural products such as vegetable extracts,
fruits extracts, and fish extracts, and found that extracts from eel muscles significantly pro‐
tected against Zn-induced neurotoxicity [26]. Finally, we demonstrated that carnosine (ß-
alanyl histidine), a small hydrophilic peptide abundant in eel muscles, protected GT1-7 cells
from Zn-induced neurotoxicity in a dose-dependent manner. Therefore, we applied for the
patent on carnosine as a drug for the treatment of VD or for slowing the progress of cogni‐
tive decline after ischemia (the application No. 2006-145857; the publication No. 2007-314467
in Japan) [27]. Carnosine is a naturally occurring dipeptide and is commonly present in ver‐
tebrate tissues, particularly within the skeletal muscles and nervous tissues [28]. It is found
at high concentrations in the muscles of animals or fish which exhibit high levels of exercise,
such as horses, chickens, and whales. The concentration of carnosine in the muscles of such
animals is estimated to be 50–200 mM, and carnosine is believed to play important roles in
the buffering capacities of muscle tissue. During high-intensity anaerobic exercise, proton
accumulation causes a decrease in intracellular pH, which influences various metabolic
functions. The pKa value of carnosine is 7.01, close to intracellular pH.
Therefore, carnosine contributes to physicochemical non-bicarbonate buffering in skeletal
muscles, and the administration of carnosine has been reported to induce hyperactivity in
animals.
Carnosine  reportedly  has  various  functions  including  anti  oxidant,  anti  glycation,  anti
crosslink,  and  considered  to  be  an  endogenous  neuroprotective,  anti-aging  substances.
Considering  the  advantegeous  properties  of  carnosine  Considering  the  advantegeous
properties  of  carnosine  (relatively  non-toxic,  heat-stable,  and  water-soluble),  the  dietary
supplementation of  carnosine might be an effective strategy for  the prevention or  treat‐
ment of neurodegenerative diseases such as ischemia, VD, AD, and prion diseases. Coro‐
na  et  al.  reported  that  supplementation  of  carnosine  improved  learning  abilities  of
Alzheimer’s model mice [29].  We demonstrated that neurotoxicity of prion protein frag‐
ment was attenuated by Zn and carnosine [30].
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3. Zn and Alzheimer’s disease diseases
3.1. Amyloid cascade hypothesis and Zn
AD is a severe senile type of dementia first reported in 1906. The pathological hallmarks of
AD are the deposition of extracellular senile plaques, intracellular neurofibrillary tangles
(NFTs), and the selective loss of synapses and neurons in the hippocampal and cerebral cort‐
ical regions. The major component of NFTs is the phosphorylated tau protein. Senile pla‐
ques are largely comprised of ß-amyloid protein (AßP) [31]. Numerous biochemical,
toxicological, cell biological, and genetic studies have supported the idea termed “amyloid
cascade hypothesis” which suggests that the neurotoxicity caused by AßP play a central role
in AD [32,33]. AβP is a small peptide with 39–43 amino acid residues. It is derived from the
proteolytic cleavage of a large precursor protein (amyloid precursor protein; APP). AβP has
an intrinsic tendency to self-assemble to form sodium dodecyl sulfate (SDS)-stable oligom‐
ers. Moreover, oligomerization and conformational changes in AßP are important for its
neurodegeneration process. In an aqueous solution, freshly prepared and dissolved AβP ex‐
ists as a monomeric protein with a random coil structure. However, following incubation at
37°C for several days (aging), AβPs form aggregates (oligomers) with β-pleated sheet struc‐
tures, and finally form insoluble aggregates, termed amyloid fibrils (Fig. 5). The aged AβP
peptides were considerably more toxic to cultured neurons than fresh (freshly prepared just
before the experiment) AβP. AßP is secreted in the cerebrospinal fluid (CSF) of young indi‐
viduals as well as in aged or dementia patients [34]. Therefore, factors that accelerate or in‐
hibit the oligomerization may play essential roles in the pathogenesis of AD. Several factors
such as the concentration of peptides, pH, composition of solvents, temperature, oxidations,
mutations, and racemization of AßP can influence the oligomerization processes [35].
Interestingly, rodent AßP exhibits less tendency to oligomerization than human AßP in vitro
and the accumulation of AßP is rarely observed in the brains of rodents (rats or mice) as
compared to primates (humans or monkeys). As shown in Fig. 5, the amino acid sequences
of human and rodent AßP are similar, but rodent AßP differs from primate only 3 amino
acids (Arg5, Tyr10, and His13) from primate AßP. All three amino acids have the ability to
bind metals. Therefore, trace elements including Al, Zn, Cu, Fe as the accelerating factor of
AßP are of particularly interest.
We have investigated the metal-induced oligomerization of AßP and found that the metals
including Al, Zn, Fe, Cu, and Cd enhanced the oligomerization. However, the oligomeriza‐
tion induced by Al is more marked than that induced by other metals [36,37]. Furthermore,
while Zn-aggregated AßPs are rarely observed on the surface of cultured neurons several
days after its exposure, Al-aggregated AßPs bind tightly to the surface of cultured neurons
and form fibrillar deposits. Bush et al. reported the Zn- or Cu- induced oligomerization of
AßP [38,39], and have developed the chelation therapy for AD treatment [40]. Clioquinol
(quinoform), a chelator of Cu2+ or Zn2+, inhibits oligomerization of AßP and attenuates the
accumulation of amyloid in the brains of experimental animals. Clinical trials using its ana‐
logue PBT2 are under investigation. However, considering that the morphology of AßP
oligomers treated with metals including Al, Cu, Fe, Zn are quite different [41] and that re‐
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cent approaches using size-exclusion chromatography, gel electrophoresis, and atomic force
microscopy have demonstrated that identified soluble oligomers are neurotoxic, further
studies about metal-induced oligomerization are necessary.
APP also possesses copper/zinc binding sites in its amino-terminal domain and in the AßP
domain and may be involved in homeostasis of these metals [42]. Duce et al. demonstrated
that APP has ferroxidase activity, which converts Fe2+ to Fe3+ and regulates free pro-oxidant
Fe2+ concentrations. They also found that Zn2+ inhibits the ferroxidase activity of APP [43].
Thus, the interaction with Zn and other metals in the functions of APP are of great interst.
3.2. AßP -induced neuronal death and Zn
Zn is involved in the mechanism of AßP-induced neurotoxicity. There is considerable inter‐
est regarding the mechanism by which AßPs cause neuronal death. In 1993, Arispe et al. first
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Figure 5. Amyloid cascade hypothesis and the implications of Zn and other metals. AßP is secreted from its precursor
APP, a Zn- or Cu- binding protein. AßP monomers exhibit random-coil structures. However, during aging or in the
presence of some acceleratory factors, AßP self-aggregates and forms several types of oligomers (SDS-soluble oligom‐
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demonstrated that AßP directly incorporates into artificial lipid bilayer membranes and
forms cation-selective (including Ca2+) ion channels [44,45]. We revealed that AßP formed
amyloid channels on the GT1-7 cell membranes and their characteristics were considerably
similar to those observed on artificial lipid bilayers; cation-selective, multilevel [46]., and
that AßP causes the increase of intracellular Ca2+ in GT1-7 cells and degeneration [47]. These
results strongly support the hypothetical idea termed ‘amyloid channel hypothesis’, namely,
that the direct incorporation of AßPs and the subsequent imbalances of Ca2+ and other ions
through amyloid channels may be the primary event in AßP neurotoxicity [48].
Senile plaque
monomer oligomer
Ca2+
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AßP 
Disruption of Ca2+ homeostasis
Synaptotoxicity
synapse
Alzheimer’s disease
Neurotoxicity
FeZnCuAl
Zn
Zn
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Fe Al
Figure 6. Zn and other metals in the pathogenesis of Alzheimer’s disease. Details are shown in the text.
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Inorganic cations such as Al3+ or Zn2+ inhibit current induced by amyloid channels [44,45].
Zn reportedly  inhibited  AßP-induced Ca2+  increase.  We have  revealed that  the  amyloid
channel activity formed on membranes of GT1-7 cells was inhibited by addition of Zn2+,
and recovered by  Zn chelator,  o-phenanthroline  [47].  Considering  that  Zn  binds  to  His
residues of AßP, Arispe et al. found that histidine-related peptide derivatives such as His-
His  are  effective  in  the  inhibition  of  amyloid  channels,  the  attenuation  of  AßP-induced
[Ca2+]i  changes,  and the  protection  of  neurons  from AßP toxicity.  Among various  com‐
pounds  tested,  small  amphiphilic  pyridinium  salts  were  revealed  to  block  the  amyloid
channel and protect neurons [49].
Based on our and other findings about the link between Zn and the pathogenesis of AD, we
made a hypothetical scheme about the link between AD pathogenesis and Zn (Fig. 6). AßPs
are normally secreted from APP, which exists in the synapse. Secreted AßPs are usually de‐
graded proteolytically by proteases within a short period. However, Zn or other metals en‐
hance the oligomerization and accumulation of AßP. After incorporation into the
membrane, the conformation of AßPs change and the accumulated AßPs aggregate on the
membranes.. Finally, aggregated AßP oligomers form ion channels leading to the various
neurodegenerative processes.Unlike endogenous Ca2+ channels, these AßP channels are not
regulated by usual blockers. Thus, once formed on membranes, a continuous flow of [Ca2+]i
is initiated. Disruption of calcium homeostasis triggers several apoptotic pathways and pro‐
motes numerous degenerative processes, including free radical formation and tau phos‐
phorylation, thereby accelerating neuronal death. Meanwhile, Zn2+, which are secreted into
synaptic clefts in a neuronal activity-dependent manner, inhibit AßP-induced Ca2+ entry,
and thus have a protective function in AD.
4. Conclusion
Based on results of our own and other numerous studies, the disruption of Zn homeostasis,
namely both zinc depletion and excess zinc, cause severe damage to neurons and linked
with various neurodegenerative diseases including VD and AD. Increasing evidence sug‐
gests the implications of Zn in the pathogenesis of other neurodegenerative disease includ‐
ing prion diseases, Parkinson disease, ALS etc. Zn acts as a contributor of the disease in one
part, and as a protector in another part. Thus, Zn might play a role like that of Janus, an an‐
cient Roman god of doorways with two different faces, in the brain (Fig. 7).
Our new approach to ischemia-induced neurodegeneration from the perspective of the Zn
hypothesis will lead to new therapeutic tools for the treatment and/or prevention of VD.
Further research about the role of Zn in neuronal injury and the significance of Zn homeo‐
stasis might give rise to the development of new treatments for neurodegenerative diseases.
In this context, the advantegeous properties of carnosine (relatively non-toxic, heat-stable,
and water-soluble) as a possible candidate for the prevention or treatment of neurodegener‐
ative diseases such as ischemia, VD, AD, and prion diseases are important.
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Figure 7. Zn as Janus in brain
As described here, Zn plays important roles in memory formation, and protects neurons
from various neurodegenerative diseases. Meanwhile, excess Zn is neurotoxic and may en‐
hance the pathogenesis of the diseases.
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